Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 17.32
-0.04 (-0.23%)
Aug 21, 2026, 3:04 PM CST
SHE:300497 Revenue
Jiangxi Fushine Pharmaceutical had revenue of 530.49M CNY in the quarter ending June 30, 2026, with 88.80% growth. This brings the company's revenue in the last twelve months to 1.56B, up 54.30% year-over-year. In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B with 0.61% growth.
Revenue (ttm)
1.56B
Revenue Growth
+54.30%
P/S Ratio
5.99
Revenue / Employee
n/a
Employees
1,663
Market Cap
9.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18B | 7.14M | 0.61% |
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.93B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Chengdu Easton Biopharmaceuticals | 1.34B |
| Liaoning Chengda Biotechnology | 1.31B |
| Hualan Biological Vaccine | 1.20B |
| Bio-Thera Solutions | 980.25M |
| Daan Gene | 737.96M |